A detailed history of Simplex Trading, LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Simplex Trading, LLC holds 449 shares of IFRX stock, worth $686. This represents 0.0% of its overall portfolio holdings.

Number of Shares
449
Previous 301 49.17%
Holding current value
$686
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$1.18 - $1.74 $174 - $257
148 Added 49.17%
449 $0
Q1 2024

Apr 25, 2024

SELL
$1.47 - $2.03 $1,866 - $2,578
-1,270 Reduced 80.84%
301 $0
Q4 2023

Feb 02, 2024

SELL
$1.25 - $2.75 $7,388 - $16,255
-5,911 Reduced 79.0%
1,571 $2,000
Q3 2023

Nov 01, 2023

SELL
$2.66 - $4.33 $46,417 - $75,558
-17,450 Reduced 69.99%
7,482 $22,000
Q2 2023

Aug 04, 2023

BUY
$2.05 - $6.1 $26,420 - $78,616
12,888 Added 107.01%
24,932 $111,000
Q1 2023

Apr 27, 2023

SELL
$1.66 - $3.1 $27,964 - $52,222
-16,846 Reduced 58.31%
12,044 $23,000
Q4 2022

Feb 02, 2023

BUY
$2.11 - $3.25 $47,342 - $72,920
22,437 Added 347.7%
28,890 $89,000
Q3 2022

Nov 04, 2022

BUY
$1.32 - $3.14 $873 - $2,078
662 Added 11.43%
6,453 $17,000
Q2 2022

Aug 03, 2022

BUY
$0.78 - $1.9 $1,517 - $3,695
1,945 Added 50.57%
5,791 $8,000
Q2 2021

Aug 12, 2021

SELL
$2.72 - $4.04 $2,758 - $4,096
-1,014 Reduced 20.86%
3,846 $11,000
Q1 2021

Apr 26, 2021

BUY
$3.62 - $6.34 $445 - $779
123 Added 2.6%
4,860 $18,000
Q4 2020

Feb 02, 2021

BUY
$3.82 - $5.32 $18,095 - $25,200
4,737 New
4,737 $23,000
Q3 2020

Oct 14, 2020

SELL
$3.7 - $5.47 $13,745 - $20,321
-3,715 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$4.59 - $8.96 $17,051 - $33,286
3,715 New
3,715 $17,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $67.6M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.